Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2012
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg
Details : Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. It is indicated for chronic idiopathic constipation and IBS with const...
Product Name : Amitiza-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2023
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2017
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2017
Lead Product(s) : Lubiprostone
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2016
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lubiprostone for Chronic Idiopathic Constipation Treatment
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2016
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lubiprostone for Treatment of Chronic Idiopathic Constipation
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2016
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lubiprostone for the Treatment of Chronic Idiopathic Constipation
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2016
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2015
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lubiprostone for Children With Constipation
Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2014
Lead Product(s) : Lubiprostone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
